NeoGenomics, Inc.
NEO
Positions held
Your positionsNEO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- NeoGenomics operates in the growing diagnostics and research sector, which is increasingly vital for personalized medicine and cancer treatment.
- In Q2 2026, NeoGenomics reported a revenue increase of 8% compared to the previous quarter, reaching $202 million.
- The gross margin improved to 45.6% in Q2 2026, up from 43.3% in Q1 2026.
- The company has a negative profit margin of -6.77%, indicating ongoing financial challenges.
- In 2025, NeoGenomics reported a net income loss of $108.025 million, reflecting ongoing operational difficulties.
- The operating margin remains negative at -12.12% for the year 2025, highlighting persistent inefficiencies.
Fundamentals
| Market cap | $2.06B | Enterprise value | $2.36B | Trailing P/E | — | Forward P/E | 47.24 |
| PEG | 2.09 | Price / book | 2.61 | Beta | 1.78 | Dividend yield | 0.00% |
| Revenue growth | 11.2% | Earnings growth | — | Gross margin | 43.9% | Operating margin | -4.8% |
| Profit margin | -6.8% | ROE | -6.3% | ROA | -1.9% | Debt / equity | 0.57 |
| Current ratio | 3.60 | Free cash flow | $43.90M | Analyst recommendation | buy | Mean target | $21.55 |
| 52w high | $20.15 | 52w low | $7.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $202M | $187M | $190M | $188M | $181M | — |
| Op margin | -4.8% | -9.8% | -6.7% | -10.6% | -15.2% | — |
| Net income | $2.2M | -$17.1M | -$9.9M | -$27.1M | -$45.1M | — |
| Gross margin | 45.6% | 43.3% | 43.8% | 42.8% | 42.6% | — |
| Gross profit | $91.9M | $80.9M | $83.3M | $80.4M | $77.3M | — |
| Operating income | -$9.8M | -$18.2M | -$12.8M | -$19.9M | -$27.6M | — |
- Revenue +8% vs prior quarter ($202M vs $187M).
- Gross margin 45.6% (was 43.3% prior quarter).
- Operating margin expanded to -4.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $727M | $661M | $592M | $510M | — |
| Op margin | -12.1% | -12.9% | -16.3% | -30.0% | — |
| Net income | -$108M | -$78.7M | -$88.0M | -$144M | — |
| Gross margin | 43.2% | 43.9% | 41.3% | 36.9% | — |
| Gross profit | $314M | $290M | $245M | $188M | — |
| Operating income | -$88.1M | -$85.4M | -$96.6M | -$153M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Why NeoGenomics (NEO) Stock Is Up Today
2026-10-06 · Stryker, Neogenomics Announce CEO Transitions; Both Stocks Dive
2026-10-06 · NeoGenomics on 'More Solid Footing' With Strong Revenue Growth, Needham Says
2026-10-06 · NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat
2026-10-06 · Did Strong Q3 Outlook and New CEO Plan Just Shift NeoGenomics' (NEO) Investment Narrative?
2026-10-06 · Needham & Co Adjusts NeoGenomics Price Target to $22 From $19, Maintains Buy Rating
2026-10-06 · BTIG Upgrades NeoGenomics to Buy From Neutral, Price Target is $28
2026-10-05 · NeoGenomics stock falls on CEO transition announcement
2026-10-05 · NeoGenomics Names Warren Stone as Next CEO; Reports Q3 Revenue Guidance
2026-10-05 · NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
2026-09-24 · Why Women-Run Companies Deserve a Place in Your Portfolio
2026-09-23 · 3 Healthcare Stocks We’re Skeptical Of
Price (daily)
Full chart · RSI · MACD · patterns